Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing

Pharmacological administration of FGF21 analogues has shown robust body weight reduction and lipid profile improvement in both dysmetabolic animal models and metabolic disease patients. Here we report the design, optimization, and characterization of a long acting glyco-variant of FGF21. Using a com...

Descripción completa

Detalles Bibliográficos
Autores principales: Weng, Yan, Ishino, Tetsuya, Sievers, Annette, Talukdar, Saswata, Chabot, Jeffrey R., Tam, Amy, Duan, Weili, Kerns, Kelvin, Sousa, Eric, He, Tao, Logan, Alison, Lee, Darwin, Li, Dongmei, Zhou, Yingjiang, Bernardo, Barbara, Joyce, Alison, Kavosi, Mania, O’Hara, Denise M., Clark, Tracey, Guo, Jie, Giragossian, Craig, Stahl, Mark, Calle, Roberto A., Kriz, Ron, Somers, Will, Lin, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844872/
https://www.ncbi.nlm.nih.gov/pubmed/29523796
http://dx.doi.org/10.1038/s41598-018-22456-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844872/
https://www.ncbi.nlm.nih.gov/pubmed/29523796
http://dx.doi.org/10.1038/s41598-018-22456-w

Ejemplares similares